Charles River Announces Strategic Partnership with Cypre, Expanding 3D In Vitro Services for Cancer Immunotherapy and Targeted Therapy Drug Screening - Seite 2

Approved Quotes

• “Immunotherapy is a complex, yet promising area of development in cancer treatment. Cypre’s platform enables the ideal tumor culturing conditions for assaying various immunotherapies and targeted therapies and provides robust, reproducible data sets without compromising throughput that strongly correlates to our PDX in vivo results. By broadening our 3D in vitro services with this collaboration, we can provide our clients with a complete, integrated tumor model service platform.” – Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services, Charles River
• “Charles River is the premier CRO in discovery and early development services, and we are thrilled to partner with their team to drive a combined offering. Our Falcon-X platform provides Charles River customers with expanded access to patient-derived 3D in vitro screening services and a new way to assay the immune cell compartment within the tumor microenvironment. We look forward to building this relationship and providing more customers with our unique solution that will improve targeted and immuno-therapeutic options for cancer patients.” – Kolin Hribar, PhD, Founder and CEO, Cypre

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

About Cypre

Cypre has developed Falcon-X, the 3D in vitro tumor model platform that assays targeted and immuno-therapy efficacy in the tumor microenvironment. We are now applying this approach with strategic partners for therapeutic discovery, lead validation, and precision medicine. To learn more about us, visit www.cypre.co.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005203/en/